Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience

Journal of Chemotherapy

Volumn 25, Issue 6, 2013, Pages 341-346

  Santos, Paul D ^a   Davis, Amanda ^b   Jandourek, Alena ^c   Smith, Alexander ^c   Friedland, H David ^c  

^a Lakes Region General Hospital   (United States)

^b United Samaritans Medical Cent   (United States)

^c Cerexa Inc   (United States)

Author keywords

Absssi; Acute bacterial skin and skin structure infection; CAPTURE; Ceftaroline fosamil; Diabetes mellitus; MRSA; Obesity; Peripheral vascular disease

Indexed keywords

CEFTAROLINE FOSAMIL; CEPHALOSPORIN DERIVATIVE; GLYCOPEPTIDE; LINCOSAMIDE; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; SULFONAMIDE;

ABSCESS; ADULT; AGED; ARTICLE; CELLULITIS; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; OBESITY; PERIPHERAL VASCULAR DISEASE; RETROSPECTIVE STUDY; SKIN INFECTION; SKIN STRUCTURE; ULCER; UNSPECIFIED SIDE EFFECT; WOUND INFECTION;

ABSSSI,; ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION,; CAPTURE,; CEFTAROLINE FOSAMIL,; DIABETES MELLITUS,; MRSA,; OBESITY; PERIPHERAL VASCULAR DISEASE,;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CEPHALOSPORINS; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN; SKIN DISEASES, BACTERIAL; SKIN DISEASES, INFECTIOUS; STAPHYLOCOCCAL INFECTIONS; YOUNG ADULT;

EID: 84896723911     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947813Y.0000000144     Document Type: Article

References (30)

1. Templer SJ, Brito MO. Bacterial skin and soft tissue infections. Hosp Physician. 2009;45:9-26.
2. Edelsberg J, Taneja C, Zervos M, Haque N, Moore C, Reyes K, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009;15:1516-8.
3. Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2007;357:380-90.
4. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763-71.
5. Dukic VM, Lauderdale DS, Wilder J, Daum RS, David MZ. Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis. PLoS ONE. 2013;8(1):e52722.
6. Rajan S. Skin and soft-tissue infections: classifying and treating a spectrum. Cleve Clin J Med. 2012;79(1):57-66.
7. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. EMERGEncy ID Net Study Group. Methicillin-resistant Staphylococcus aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666-74.
8. Huang H, Flynn NM, King JH, Monchaud C, Morita M, Cohen SH. Comparisons of community-associated methicillinresistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California. J Clin Microbiol. 2006;44(7):2423-7.
9. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillinresistant Staphylococcus aureus USA 300 clone as the pre-dominant cause of skin and soft-tissue infections. Ann Intern Med. 2006;144:309-17.
10. Davis SL, Perri MB, Donabedian SM, Manierski C, Singh A, Vager D, et al. Epidemiology and outcomes of communityassociated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol. 2007;45(6):1705-11.
11. Skiest DJ, Brown K, Cooper TW, Hoffman-Roberts H, Mussa HR, Elliott AC. Prospective comparison of methicillin-suscep-tible and methicillin-resistant community-associated Staphylococcus aureus infections in hospitalized patients. J Infect. 2007;54:427-34.
12. Popovich KJ, Weinstein RA, Hota B. Are communityassociated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? Clin Infect Dis. 2008;46:787-94.
13. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, et al. Comparison of communityand health care-associated methicillin-resistant Staphylococcus infection. JAMA. 2003;290(22):2976-84.
14. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med. 1998;104(Suppl 5A):7S-10S.
15. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis. 2008;46:668-74.
16. Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti-infective Ther. 2004;2(1):51-9.
17. Cubist Pharmaceuticals, Inc. CubicinH (daptomycin for injection) Prescribing information, 2012. Lexington (MA): Cubist Pharmaceuticals, Inc.; 2012 [cited 2013 Apr 3]. Available from: http://www.cubist.com/downloads/PrescribingInformation.pdf
18. Marot JC, Jonckheere S, Munyentvali H, Belkhir L, Vandercam B, Yombi JC. Tigecycline-induced acute pancreatitis: about two cases and review of the literature. Acta Clin Belg. 2012;67(3):229-32.
19. Hung WY, Kogelman L, Volpe G, Iafrati M, Davodson L. Tigecycline-induced acute pancreatitis: case report and literature review. Int J Antimicrob Agents. 2009;34(5):486-9.
20. Kadoyama K, Sakaeda T, Tamon A, Okuno Y. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system. Biol Pharm Bull. 2012;35(6):967-70.
21. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54:1699-709
22. McGovern PC, Wible M, El-Tahtawy A, Biswas P, Meyer RD. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents. 2013;41:463-7.
23. Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. In vitro activity of ceftaroline against multidrug- resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillan ceSantos et al. CAPTURE-ceftaroline in ABSSSI Program (2008-2010). Clin Infect Dis. 2012;55(S3):S206-214.
24. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Kroeger JS, et al. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009. Antimicrob Agents Chemother. 2011;55(9):4154-60.
25. Saravolatz L, Pawlak J, Johnson L. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2010;54(7):3027-30.
26. Biek D, Critchley IA, Riccobene TA, Thye DA. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. J Antimicrob Chemother. 2010; 65Suppl 4: iv9-16.
27. Ishikawa T, Matsunaga N, Tawada H, Kuroda N, Nakayama Y, Ishibashi Y, et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem. 2003;11(11):2427-37.
28. Bjornsdóttir S, Gottfredsson M, Thórisdóttir AS, Gunnarsson GB, Rikardsdóttir H, Kristánsson M, et al. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin Infect Dis. 2005;41:1416-22.
29. Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51(6):641-50.
30. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65Suppl 4: iv67-71.